Industry
Drug Manufacturers - General
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Loading...
Open
55.19
Mkt cap
111B
Volume
10M
High
55.52
P/E Ratio
-15.28
52-wk high
56.80
Low
54.49
Div yield
0.04
52-wk low
39.35
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 7:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 4:40 pm
Portfolio Pulse from Benzinga Insights
August 22, 2024 | 3:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Insights
August 21, 2024 | 7:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:01 am
Portfolio Pulse from Benzinga Insights
August 16, 2024 | 5:16 pm
Portfolio Pulse from Vandana Singh
August 15, 2024 | 2:38 pm
Portfolio Pulse from Vandana Singh
August 14, 2024 | 6:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.